Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.63 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554139 | 0.83 | ADORA2A (0.54) | ADORA1ADORA2AADORA2B | |
| SCHEMBL3456558 | 0.83 | ADORA1 (0.57) | ADORA1ADORA2AADORA2BPDE3BPDE3A | |
| SCHEMBL4330714 | 0.82 | ADORA2A (0.57) | ADORA1ADORA2AADORA2BCDK5CDK5R1 | |
| SCHEMBL1553753 | 0.82 | ADORA1 (0.61) | ADORA1ADORA2A | |
| SCHEMBL4098775 | 0.79 | ADORA2A (0.45) | ADORA1ADORA2AADORA2BPDE3BPDE3A | |
| SCHEMBL5452133 | 0.78 | ADORA1 (0.62) | ADORA1ADORA2AADORA2BALDH1A1MAPT | |
| SCHEMBL6133799 | 0.78 | ADORA2A (0.54) | ADORA1ADORA2AADORA2BPDE3BPDE3A | |
| SCHEMBL1553927 | 0.77 | ADORA2A (1.00) | ADORA1ADORA2AADORA2BALDH1A1MAPT | |
| SCHEMBL1554689 | 0.77 | ADORA1 (0.59) | ADORA1ADORA2AADORA2BALDH1A1MAPT | |
| SCHEMBL1553736 | 0.77 | ADORA2A (0.44) | ADORA1ADORA2AADORA2BPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101928282-B | Process for preparing pyrimidine compounds | SANITATION MATERIAL R & D MAN CO LTD | 2012-02-29 | — | — | CN | disclosed |
| EP-1439175-B1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-1439175-B1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2011-04-27 | — | — | EP | disclosed |
| CN-101103024-B | Crystal and amorphous form of pyrimidine compound and process for producing the same | EISAI R&D MAN CO LTD | 2011-03-16 | — | — | CN | disclosed |
| CN-101928282-A | Process for preparing pyrimidine compounds | SANITATION MATERIAL R & D MAN CO LTD | 2010-12-29 | — | — | CN | disclosed |
| EP-2246344-A1 | Pyrimidine compounds and medicinal composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-7767812-B2 | Crystals of pyrimidine compound and process for producing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767812-B2 | Crystals of pyrimidine compound and process for producing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767812-B2 | Crystals of pyrimidine compound and process for producing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| EP-2210889-A1 | Process for producing pyrimidine compound | Eisai R&D Management Co., Ltd. (JP) | 2010-07-28 | — | — | EP | disclosed |
| EP-1862463-A1 | PYRIMIDINE COMPOUND CRYSTAL OR AMORPHOUS FORM AND PROCESS FOR PRODUCING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2007-12-05 | — | — | EP | disclosed |
| EP-1862463-A1 | PYRIMIDINE COMPOUND CRYSTAL OR AMORPHOUS FORM AND PROCESS FOR PRODUCING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2007-12-05 | — | — | EP | disclosed |
| EP-1840128-A1 | CRYSTAL OF 5-[2-AMINO-4-(2-FURYL)PYRIMIDIN-5-YL]-1- METHYLPYRIDIN-2(1H)-ONE AND PROCESS FOR PRODUCING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-20070078151-A1 | Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds | EISAI CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20070078151-A1 | Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds | EISAI CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20070078151-A1 | Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds | EISAI CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20060235225-A1 | Crystals of 5-[2-amino-4-(2-furyl) pyrimidin-5-yl]-1-methylpyridin-2(1H)-one and processes for preparing the same | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| CN-1575290-A | Pyrimidine derivatives and pharmaceutical compositions containing that compounds | EISAI CO LTD (JP) | 2005-02-02 | — | — | CN | disclosed |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1439175-A1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078151-A1 | Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds | UMPS, TYMP, UPP1 | ADORA1 131/4885ADORA2A 199/4885ADORA2B 554/4885 |
| US-20060235225-A1 | Crystals of 5-[2-amino-4-(2-furyl) pyrimidin-5-yl]-1-methylpyridin-2(1H)-one and processes for preparing the same | APC, MLN, CROCC | ADORA1 695/4885ADORA2A 826/4885ADORA2B 2663/4885 |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | ADORA2B, ADORA2A, ADORA3 | ADORA1 4/4885ADORA2A 2/4885ADORA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.